In the adjuvant setting, trastuzumab was the cornerstone of the anti-HER2 therapy for the treatment of HER2+ breast cancer until recently, when results of T + P and neratinib after T were approved (11–13). The gene discussed is ERBB2; the disease is breast carcinoma.